Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs

T. Stürmer1, R. Wyss1, R. J. Glynn2 & M. A. Brookhart1

From the 1Department of Epidemiology, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC; and 2Division of Preventive Medicine & Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA


Treatment effects, especially when comparing two or more therapeutic alternatives as in comparative effectiveness research, are likely to be heterogeneous across age, gender, co-morbidities and co-medications. Propensity scores (PSs), an alternative to multivariable outcome models to control for measured confounding, have specific advantages in the presence of heterogeneous treatment effects. Implementing PSs using matching or weighting allows us to estimate different overall treatment effects in differently defined populations. Heterogeneous treatment effects can also be due to unmeasured confounding concentrated in those treated contrary to prediction. Sensitivity analyses based on PSs can help to assess such unmeasured confounding. PSs should be considered a primary or secondary analytic strategy in nonexperimental medical research, including pharmacoepidemiology and nonexperimental comparative effectiveness research.

Keywords: comparative effectiveness research, confounding, epidemiologic methods, heterogeneity, pharmacoepidemiology, propensity scores.

Randomized controlled trials (RCTs) are considered the gold standard for assessing the efficacy of medical interventions, including medications, medical procedures and clinical strategies. Nevertheless, particularly for research on the prevention of chronic disease, RCTs are often not feasible because of the size that would be required to address rare outcomes, timeliness, budget requirements and ethical constraints [1]. Nonexperimental studies of medical interventions are not subject to these limitations, but have frequently been criticized because of their potential for confounding bias [2, 3]. This concern reached a crescendo with the disparity in estimated effects of postmenopausal hormone therapy on the risk for cardiovascular events from RCTs and nonexperimental studies.[4] These discrepancies highlighted the need to develop and apply improved methods to reduce bias in nonexperimental studies in which confounding is likely [5].

Rosenbaum and Rubin [6] developed the method of the propensity score (PS) as an alternative to multivariable outcome models for confounding control in cohort studies. PSs have become increasingly popular to control for measured confounding in nonexperimental (epidemiologic or observational) studies that assess the outcomes of drugs and medical interventions [7]. Whilst not generally superior to conventional outcome models [8], PSs focus on the design of nonexperimental studies rather than the analysis [9]. Combined with the new user design [10], PSs specifically focus on decisions related to initiation of treatment and hypothetical interventions [11].

By comparing the distribution of PSs between the treated and untreated cohorts, PSs permit ready assessment to determine whether or not the treated and untreated patients are fully comparable [12, 13]
and identification of patients treated contrary to prediction [14]. Based on these recent developments, a re-analysis of the data from the Nurses’ Health Study [15] and an analysis of the Women’s Health Initiative observational study [4] on the effects of oestrogen and progestin therapy on coronary heart disease in postmenopausal women that followed a new user design and dealt with selection bias after initiation showed results compatible with the ones from RCTs.

Herein, we review the concept of PSs, the implementation of PSs and specific issues relevant to nonexperimental studies of medical interventions. The aim of the review was to help clinical researchers understand specific advantages of PSs, to appropriately implement PSs in research and to evaluate the studies using PSs from the medical literature. Our focus was on issues that are relevant for making valid treatment comparisons, and we therefore start with some general topics that are important to understand the specific benefits of PSs for medical research.

Variability in treatment decisions
Medical decision-making is complex and influenced by many factors. Whilst patient characteristics (e.g. disease progression, unrelated co-morbidities, co-medications and life expectancy) are important determinants of treatment choice, treatment decisions are also influenced by a wide variety of factors that are largely independent of the patient’s health, including calendar time, physician training, healthcare setting (including financial pressures), detailing on the physicians’ side and various forms of direct-to-consumer advertising, beliefs (including religion), family and others (e.g. household help).[16] Note that some of these factors can be measured, whilst many are either unmeasured or even unknown.

For nonexperimental research, however, the more important distinction is whether or not factors influencing the treatment decision are independent of the risk for the outcome under study. Only those factors affecting treatment decisions that also affect the risk for the outcome of interest are confounders, and if unaccounted for, lead to biased estimation of treatment effects. Factors affecting treatment decisions that are unrelated to the outcome of interest, measured or not, are the factors that allow us to do nonexperimental research of medical interventions. If all the variation in treatments is related to the risk for the outcome, we are unable to estimate the treatment effect. This setting has been termed ‘structural confounding’.[12] In medical research, we are often confronted with something in between these two extremes termed ‘confounding by indication’: some of the variability in treatments, but not all of the variability is a function of disease severity (the indication).[5]

Because disease severity is difficult to measure, some have strongly argued against nonexperimental research for intended effects of medical interventions [1, 3, 17]. If all physicians and their patients would make the same treatment decision based solely on uniform and reliable measures of disease severity (indication), then we would indeed be unable to study medical interventions outside of RCTs. When comparing treated to untreated persons, confounding by indication is often intractable. Fortunately, in actual medical practice, we often have a choice of interventions and a range of views amongst physicians and patients about appropriateness of treatment and willingness to choose it. For example, there are several long-acting insulins on the market. Guidelines for treatment of persistent asthma offer a choice of treatments for most of the different stages of severity. Comparing treatments that are indicated for the same stage of disease progression drastically limits the potential for confounding by indication. A comparative study of two treatments also eliminates confounding by frailty that results when comparing patients receiving preventive treatments with untreated patients [16, 18, 19].

Confounding
Confounding is a mixing of effects [20]. This can be depicted using the following causal diagram (Fig. 1).

A classic example of confounding (by indication) is the estimation of the effects of beta agonists on asthma mortality. Patients with more severe asthma are more likely to be treated with beta agonists (at any point in time), and asthma severity is an independent predictor of asthma mortality. To depict this confounding by indication using purely hypothetical numbers, we have dichotomized the treatment into yes (E = 1) or no (E = 0) and asthma severity into severe asthma (X = 1) and less severe asthma (X = 0) (Fig. 2).
Treatment effect heterogeneity

It is reasonable to assume that treatment effects (both intended and unintended) are not the same in every patient. Good candidates for treatment effect heterogeneity are age (e.g. children and older adults), gender, disease severity, co-morbidity (e.g. diabetes) and co-medication (e.g. ‘polypharmacy’), which are relatively easy to study.

Examples of clinically relevant treatment effect heterogeneity include adjuvant chemotherapy with oxaliplatin in patients with stage III colon cancer, which has been shown to improve survival in patients with a median age of 60 years [21], but may not do so in patients above age 75 years [22], and the primary prevention of myocardial infarction with low-dose aspirin in men [23], but not women [24].

Treatment effect heterogeneity has consequences for the estimation of overall treatment effects. If the effect of treatment with beta agonists is more pronounced in those with severe asthma, the proportion of patients with severe asthma in the study population will influence the estimation of any overall treatment effect (Fig. 3). The overall treatment effect in the population will be a weighted average of the treatment effect in those patients with severe asthma and those patients with less severe asthma. The ability to define the population studied (e.g. a population in which the prevalence of severe asthma is 20%) becomes essential and is a critical component of principled ‘causal inference’. [25–27] Our focus herein will be on the relative risk (RR). Homogeneous RRs generally imply treatment effect heterogeneity on the risk difference scale if the treatment has an effect and vice versa.

Propensity scores

Theory

The PS is a covariate summary score defined as the individual probability of treatment (exposure) given (conditional on) all confounders [6]. In our example, 50% of those with severe asthma receive beta agonists, so every patient with severe asthma will have a PS of 0.5 whether or not the patient was actually treated. Whilst in practice there may be different covariate patterns that lead to a PS of 0.5, Rosenbaum and Rubin [6] proved that treated and untreated patients with the same PS value (e.g. treated patients with a PS of 0.5 and untreated patients with a PS of 0.5) will, on average, have the same distribution of covariates used to estimate the PS. Thus, by holding the PS constant (conditioning on the PS) treated and untreated cohorts will tend to be ‘exchangeable’ with respect to the covariates. Exchangeability, in return, leads to unconfounded estimates of treatment effects because it removes the arrow from the covariate(s) to the treatment (Fig. 1 above). Note that exchangeability is restricted to measured covariates whose relation to treatment is correctly mod-
elled in the PS. We therefore need to assume no unmeasured confounding, which is much more plausible with randomization, another method to obtain exchangeability.

The ability to control for confounding using PSs is, in general, not different from what we would achieve using a more conventional multivariable outcome model [8], but the PS has some specific advantages outlined below. The PS also allows us to clearly define the study population in the presence of treatment effect heterogeneity, something that cannot be achieved using a conventional multivariable outcome model [28]. We will now provide a nontechnical description of PS estimation and implementation.

Estimation

The PS is usually estimated using multivariable logistic regression. The few published direct comparisons between logistic regression and other methods to estimate the PS (e.g. neural networks [29]; boosted CART [30, 31]) found that PS performs well in most settings. More recently, PS estimation methods based on optimizing balance have been proposed [32]. These are promising, but their performance and causal implications have not yet been thoroughly assessed. It is thus reasonable to use logistic regression to estimate PSs.

As with any model, mis-specification of the PS can lead to bias. An advantage of PSs is that we can check the performance of the model by assessing covariate balance across treatment groups after stratifying, matching, or weighting on the estimated PS (PS implementation discussed below). If covariate imbalances remain, the PS model can be refined, for example using less restrictive terms for continuous covariates (e.g. squared or cubic terms, fractional polynomials and splines) or by adding interaction terms between covariates.

Although the ability to check covariate balance is a beneficial aspect of PS methods, there is no agreed-upon best way to check or summarize covariate balance. The vast majority of the current methods proposed to quantify covariate imbalances do not take the confounding potential of the remaining imbalances into account. We therefore suggest using the approach proposed by Lunt et al. [33] that assesses the confounding potential of remaining imbalances by assessing the change in estimate after controlling for individual covariates in the outcome model after PS implementation. A change in estimate indicates a remaining imbalance of the covariate across treatment groups and that the covariate affects the risk for the outcome independent of treatment. A graphical depiction of the spread of the changes in estimate can then be used to compare different PS estimation or implementation methods [33].

As in any nonexperimental study, the process of variable selection is also important for PS models. The crux lies in the inability of the data to inform us about causal structures. In fact, data cannot be analysed without the researcher imposing a causal structure [34].

Thus far, we have depicted the PS as a model predicting treatment based on covariates. We now need to add an important distinction between the PS and a model intended to optimize discrimination between treatment groups. [35] Consider in our hypothetical study of beta agonists outlined above a random selection of the physicians treating patients with asthma has recently been visited by a detailer making a very compelling argument to treat more patients with beta agonists irrespective of asthma severity. So, we build the PS based on asthma severity (and all potential risk factors for asthma mortality, the outcome of interest) to control for confounding. Should we add the variable ‘recent detailer visit’ to the PS model? Because
the detailer visit leads to increased prescribing irrespective of asthma severity, it will clearly improve our prediction of treatment with beta agonists, but does this help with respect to our aim (i.e. to estimate the unconfounded effect of beta agonists on asthma mortality)? The answer is no, and even worse, to the contrary. Having had a detailer visit is an ‘instrumental variable’, that is a variable associated with the treatment of interest, but not affecting the outcome (asthma mortality) other than through its relation with the treatment (beta agonists).

In medical research, instrumental variables are those that explain variation in treatments, but are not directly related to the outcome of interest. As outlined above, this is the ‘good’ variability (e.g. the change in prescribing following the detailer visit). Without such variability, we would not be able to conduct nonexperimental research. By removing ‘good’ variability, we not only decrease the precision of the estimate [36], but also increase the contribution of ‘bad’ variability, that is unaccounted for variability in treatments that affects the risk for the outcome (also called unmeasured confounding) [16, 37]. This issue is not just academic [38] and the crux lies in the fact that the data will not tell us whether or not a variable is a confounder or an instrumental variable. Some have argued that it is safer to err on the side of including variables in the PS [37] or to use automated procedures to screen hundreds of potential covariates in studies using large automated healthcare databases [39]. Automated procedures have been shown to improve confounding control in some [39], but not all settings [40, 41]. They should be implemented with care and considering the potential for inclusion of instrumental variables.

Implementation

Once the PS is estimated, we can control for this covariate summary score as for any other continuous covariate using standard epidemiologic techniques, including stratification, matching, standardization (weighting) and outcome regression modelling. Modelling (adding the PS to a multivariable outcome model) is the least appealing of these implementation methods because its validity is dependent on correctly specifying two models (the PS and the outcome model), and it also does not offer specific advantages of other PS implementations, as outlined below. We therefore do not recommend implementing the PS as a continuous covariate in an outcome regression model.

One of the main advantages of the PS is that it provides an easy way to check whether or not there are some patient characteristics (covariate patterns) that define groups of patients in whom there is no variability in treatments (i.e. everyone treated or no one treated; Fig. 4). It might be that, following our beta agonists and asthma example, within the group of patients with mild asthma there is a group of patients with very mild asthma in which no one is treated with beta agonists. It is easy to see that there are no data to estimate any treatment effect in this group, unless we make the strong, and likely incorrect assumption that risk of death and treatment effects in these patients with very mild asthma would be identical to those in the group of treated patients with mild asthma. Whilst extrapolation of treatment effects to groups for whom we have no data to estimate the treatment effect may be very sensible in practice, researchers should at least be aware of such extrapolations. PSs allow us to limit model extrapolation by excluding patient groups from the analysis in whom no treatment effect can be estimated because all patients are either never (untreated with PS lower than the lowest PS in the treated) or always treated (treated with higher PS than the highest PS in the untreated). Trimming (excluding) nonoverlap regions of PS should be the default prior to any PS implementation. The untrimmed and trimmed populations need to be compared; however, because trimming patients

![Fig. 4 Schematic for nonoverlap in propensity score distributions – exclusion (trimming) of nonoverlap (shaded areas) reduces model extrapolation to covariate patterns in which no treatment comparison can be made (‘nonpositivity’).](image)
with very mild asthma (our example) leads to a focused inference that is not generalizable to all asthmatics.

Stratification of continuous covariates into equal-sized strata (percentiles), estimation of the treatment effect within these percentiles, and combining the stratum-specific estimates using a weighted average (e.g., Mantel–Haenszel; MH [42]) is a well-established method to control for confounding by any continuous covariate, including the PS. Trimming of nonoverlap should be performed before creating percentiles. Depending on the number and distribution of outcomes, it is often possible to use 10 strata (deciles) rather than the ‘usual’ five strata (quintiles), thus reducing residual confounding within strata. Because most methods to average stratum-specific estimates assume uniform treatment effects across strata, it is important to estimate and evaluate the stratum-specific treatment effect estimates before combining the stratum-specific treatment effect estimates into an overall estimate. Using our numerical example above (Fig. 2), stratifying on the PS will be the same as stratifying on asthma severity; there are only two distinct PS values (PS = 0.5 for all those with X = 1 and PS = 0.1 for all those with X = 0). Because the treatment effect is uniform (RR = 0.5 in both PS strata), we know that any weighted average, including the MH estimate, of the unconfounded effect of beta agonists on asthma mortality in our cohort will yield a RR = 0.5.

Matching on specific covariates in cohort studies removes confounding by the matching variable(s) and has been used extensively in epidemiologic research prior to the widespread availability of multivariable models [43]. Matching on a large number of covariates quickly becomes intractable; however, summary scores, including the PS, were originally proposed to overcome this limitation [44, 45]. In theory, the implementation is straightforward; for every treated patient, we find a single or multiple untreated patients with the same PS (or nearly the same PS, based on a predetermined calliper) and put the matched pair aside. We then repeat this step until we acquire all of the treated patients matched to the same number of untreated patients (a selection of all the untreated patients). In practice, however, this is more complicated because we may not find an untreated match for every treated patient. The ability to find matches for all treated patients is a complex function of the overall prevalence of the treatment in the population, the separation of the PS distribution in treated and untreated patients and the width of the PS calliper used [33, 46]. There is a general trade-off between residual confounding (minimized by narrow callipers) and finding matches (maximized by wide callipers). Various matching algorithms are available, and the comparative performance has been assessed using simulations [47]. We have often used a greedy matching algorithm [48], and this has been shown to perform well in both actual studies and simulations [47]. It is important to report the number or proportion of treated patients that could be matched. Higher proportions are preferred. Note that the proportion of untreated patients that could be matched, and therefore the overall number of patients matched, is not relevant here.

Standardization is a way to validly summarize treatment effects in the presence of treatment effect heterogeneity. Note that matching implicitly standardizes the estimate to the treated population. ‘Standardizing’ to the treated population can also be achieved using standardized mortality/morbidity ratio (SMR) weights [49] (the quotes around ‘standardizing’ are due to a technicality: we can only standardize on categories of variables, whereas weighting actually allows us to include continuous variables and is thus more flexible). These weights create a pseudo-population of the untreated, which has the same covariate distribution as the treated. Whilst every treated person receives a weight of 1 (i.e., the observed), every untreated person is weighted by the PS odds [PS/(1-PS)]:

\[
\text{SMR W} = E + (1 - E) \times (PS)/(1 - PS)
\]

We now use our numerical examples presented in Figs 2 and 3 to illustrate PS implementation to estimate the average treatment effect in the treated. For clarity, we retain the single, dichotomous covariate example in which there is no difference between controlling for this single covariate and the PS. In practice, however, the PS will be a summary score of multiple covariates reduced into a single covariate, which allows us to efficiently implement all that follows rather than doing this for each and every covariate separately. PS matching (in expectation) and SMR weighting will lead to the numbers presented in Fig. 5 and an unconfounded RR = 0.5 in the collapsed table. The
prevalence of treatment, and thus the estimated PS, is 0.1 in those with \( X = 0 \) and 0.5 in those with \( X = 1 \).

Another typical standard is the overall population of the treated and untreated. This can be achieved by implementing the PS using inverse probability of treatment weights (IPTW). In settings with an active comparator, estimating the treatment effect in the entire population obviates the need to determine which treatment to identify as treated and untreated in PS matching and SMR weighting. IPTW creates a pseudo-population of both the treated and the untreated, which has the same covariate distribution as the overall population of treated and untreated. Every person is weighted by the inverse of the probability of receiving the treatment actually received [the PS in the treated and \((1-\text{PS})\) in the untreated]. Stabilizing these weights by the marginal overall prevalence of the treatment actually received has specific advantages that are beyond the scope of this review.[27] The actual stabilized IPTW weights are easily implemented based on the estimated PS, as follows:

\[
\text{IPTW } W_{\text{Stabilized}} = \frac{E \cdot \text{PE}/\text{PS} + (1-E) \cdot (1-\text{PE})/(1-\text{PS})}{\text{Prevalence of treatment}}
\]

where \( \text{PE} \) is the overall marginal prevalence of the treatment exposure.

In our numerical example, the marginal prevalence of treatment, \( \text{PE} \), is 0.18 (Fig. 2). Using our estimated PS values would lead to the weights, and on average, the numbers presented in Fig. 6 and again to an unconfounded RR = 0.5 in the collapsed table.

In our above numerical example, all PS implementation methods led to the same unconfounded treatment effect estimate (RR = 0.5) because the treatment effect is uniform. The results for our numerical example with heterogeneous treatment effects, as introduced in Fig. 3, are shown below in Fig. 7. As can be seen, the treatment effect in the treated (PS matching or SMR) is more pronounced than the treatment effect in the population (IPTW). Note that all estimates are unconfounded. The difference between the estimates from MH, PS matching or SMR, and IPTW is due to the fact that...
the prevalence of severe asthma, in which the treatment is effective, is higher in treated patients (55%) than the entire population of treated and untreated (20%). The MH estimate is not valid in this setting because it assumes uniform effects and the MH weighted average does not pertain to any defined population; the weights are entirely chosen to minimize variance and result in relying heavily on the stratum with severe asthma ($X = 1$) because most of the events are observed in this stratum ($w = 0.93$).

Propensity score matching, the SMR and IPTW result in so-called causal contrasts because the population of interest is clearly defined. The data (Figs 3 and 7) suggest that there is no value to use of beta agonists in those with mild asthma ($X = 0$). With such marked heterogeneity, presenting treatment effects stratified by asthma severity would be essential and any average treatment effect would have uncertain utility for treatment decisions in practice.[50]

Propensity score matching and SMR weights allow us to estimate the average treatment effect in the treated, that is in patients with the same distribution of covariates as the one actually observed in the treated. The average treatment effect in the treated answers the question, ‘What would have happened if those actually treated had not received treatment?’ In our experience, matching or SMR weighting are preferable when the comparator group is either untreated or not well defined, as is often the case in pharmacoepidemiology (although active referent groups are increasingly used in settings, such as evaluation of comparative effectiveness). Estimating the treatment effect in a population with a reasonably high prevalence of the indication for treatment reduces the potential for violations of positivity that we would likely encounter with IPTW in such a setting.

With an active comparator (a treatment alternative rather than untreated), the indication can often be assumed to be equally prevalent in both treatment groups, thus limiting the potential for violations of positivity. IPTW will often make sense with an active comparator, allowing us to estimate the average treatment effect in the entire population. This answers the question of what would have happened if everyone had been treated with ‘A’ versus what would have happened if everyone had been treated with ‘B’, the same question that is asked in an RCT [51]. Note that being able to make

![Numerical example for Mantel–Haenszel (invalid, for comparison only), standardized mortality/morbidity ratio (SMR), propensity score matching/SMR weighting and inverse probability of treatment weighting in the presence of treatment effect heterogeneity.](image)

**Fig. 7** Numerical example for Mantel–Haenszel (invalid, for comparison only), standardized mortality/morbidity ratio (SMR), propensity score matching/SMR weighting and inverse probability of treatment weighting in the presence of treatment effect heterogeneity.
these causal contrasts is dependent on predicting treatment based on relevant covariates, that is the estimation of the PS [6].

In practice, the distribution of weights needs to be carefully checked for both SMR weighting and IPTW because some patients, that is those treated contrary to prediction, receive large weights (are ‘replicated’ or ‘cloned’ many times) and thus can become highly influential. For IPTW, a rule of thumb for well-behaved weights (‘no problem’) would be a mean stabilized weight close to 1.0 and a maximum stabilized weight of < 10 [52]. Thus far, no similar rule of thumb has been evaluated for SMR weighting, but in the meantime it would seem reasonable to also use weights ≥ 10 as a sign for concern. If weights > 10 are observed, researchers should check whether or not instrumental variables can be excluded from the PS model and perform sensitivity analyses involving additional trimming (see below).

**Trimming**

Thus far, we have assumed no unmeasured confounding. Whilst this assumption is necessary to estimate treatment effects using any adjustment method, in reality the assumption of no unmeasured confounding will often be violated to some extent. Some patients that have the indication for treatment (e.g. because they have severe asthma) may be too frail to receive the treatment. Because frailty is a concept that is difficult to measure, it can lead to substantial bias in nonexperimental studies of medical interventions compared with no intervention [19, 53]. Because the PS focuses on treatment decisions, it allows us to identify patients treated contrary to prediction in whom confounding, for example by frailty, may be most pronounced. These are the untreated patients with the highest PS and the treated patients with the lowest PS (Fig. 8). Under this assumption, trimming increasing proportions of those at both ends of the overlapping PS distribution has been shown to reduce unmeasured confounding [14]. It is important to use a percentage (e.g. 1%, 2.5%, and 5%) of those treated contrary to prediction to derive cut-points for trimming only. Once these cut-point have been established, both treated and untreated below the lower and above the higher cut-points need to be excluded from the analysis to avoid introducing bias. The choice of cut-points will depend on the specific setting and the change in the treatment effect estimate across various cut-points will be more informative than any specific value, and thus, results from the whole range of trimming should be reported (in addition to the number of patients and events trimmed by treatment group). According to our experience, trimming may be especially important with IPTW, but we recommend routinely performing a sensitivity analysis based on trimming for any PS implementation method. As with any sensitivity analysis, transparency is important and untrimmed results need to always be presented together with trimmed results. As with trimming nonoverlap, as described above, additional trimming within the overlap population leads to a more focused inference that is no longer generalizable to the treated or the entire population.

**Recommendations**

Propensity scores are an alternative to multivariable outcome models to control for measured confounding. Compared with multivariable outcome models, PSs have specific advantages, including identification of barriers for treatment (e.g. older adults), the implicit consideration of relative timing of covariates and treatment (covariate should precede treatment initiation), the ability to present the resulting balance of covariates which is needed to remove confounding (exchangeability), the trimming of patients outside of a common range of covariates in whom we have no data to estimate the treatment effect, the ability to estimate causal contrasts in the presence of treatment effect heterogeneity and the ability to control for many covariates in settings with many treated and rare outcomes.[11] We have focused on causal
contrasts in the presence of heterogeneous treatment effects because we think that this issue is not well recognized by clinical researchers. Treatment effects are likely to be heterogeneous across age, gender, co-morbidities and co-medications, and PSs as implemented using matching or weighting allow us to estimate valid overall treatment effects in such settings. With strong treatment effect heterogeneity across the PS, research should attempt to pinpoint actual covariates leading to heterogeneity because identification of such patient groups might be relevant for clinical practice. For example, the data in Figs 3 and 7 raise the possibility that treatment has no benefit in those with $X = 0$, but has an even greater benefit in those with $X = 1$ than the estimated overall treatment effect. This might spur further evaluation of subgroup-specific effects and consideration of shifts in the population targeted for treatment. With an unexposed comparison group, estimating the treatment effect in the treated (PS matching or SMR weighting) will often be preferred because we would rarely want to treat everyone who is currently not treated. In the setting of an active comparator (e.g., comparative effectiveness research), estimating the treatment effect in the entire population (IPTW) will often make most sense because we are focusing on treatment choice after the treatment decision per se has been made. Heterogeneous treatment effects can also be due to unmeasured confounding concentrated in those treated contrary to prediction. Sensitivity analyses based on PSs allow us to assess the potential for and reduce such unmeasured confounding.

Conflict of interest statement

None of the authors has a conflict of interest with respect to the content of this manuscript.

Funding

This study was funded by R01 AG023178 from the National Institute on Aging at the National Institutes of Health.

References

Review: Propensity scores for study design


22 Sanoff HK, Carpenter WR, Stürmer T et al. The effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75. *J Clin Oncol* 2012; **30**: 2624–34.


Correspondence: Til Stürmer, MD, MPH, PhD, Department of Epidemiology, UNC Gillings School of Global Public Health, University of North Carolina at Chapel Hill, McGavran-Greenberg, CB # 7435, Chapel Hill, NC 27599-7435, USA.

(fax: +1 919 966 2089; e-mail: til.sturmer@post.harvard.edu)